Overview

Gene Location [1]
11q13.3
Pathway
Receptor tyrosine kinase/growth factor signaling
Gene
FGF19

FGF19 Mutation is present in 0.38% of AACR GENIE cases, with lung adenocarcinoma, cutaneous melanoma, colon adenocarcinoma, melanoma of unknown primary, and breast invasive ductal carcinoma having the greatest prevalence [4].

Top Disease Cases with FGF19 Mutation

Significance of FGF19 Mutation in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Cholangiocarcinoma +

Endometrial Carcinoma +

Esophageal Carcinoma +

Ovarian Carcinoma +

Cancer +

Hepatocellular Carcinoma +

Squamous Cell Lung Carcinoma +

Gastric Carcinoma +

Multiple Myeloma +

Myeloproliferative Neoplasm +

Nasopharyngeal Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.